1. Home
  2. SOS vs PLUR Comparison

SOS vs PLUR Comparison

Compare SOS & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SOS

SOS Limited

SELL

Current Price

$3.57

Market Cap

4.3M

Sector

Finance

ML Signal

SELL

Logo Pluri Inc.

PLUR

Pluri Inc.

SELL

Current Price

$0.91

Market Cap

12.5M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SOS
PLUR
Founded
2004
2001
Country
China
Israel
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3M
12.5M
IPO Year
2005
2026

Fundamental Metrics

Financial Performance
Metric
SOS
PLUR
Price
$3.57
$0.91
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 303.1K
62.3K
Earning Date
10-07-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 31.46
EPS
★ N/A
N/A
Revenue
N/A
★ $1,016,000.00
Revenue This Year
N/A
$902.46
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.17
$0.85
52 Week High
$2.08
$3.94

Technical Indicators

Market Signals
Indicator
SOS
PLUR
Relative Strength Index (RSI) 96.34 39.73
Support Level $1.00 $0.88
Resistance Level N/A $1.85
Average True Range (ATR) 0.09 0.13
MACD 0.22 -0.03
Stochastic Oscillator 91.12 10.61

Price Performance

Historical Comparison
SOS
PLUR

About SOS SOS Limited

SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing and other Hosting services. The company has single reporting segment: Commodity trading and generates key revenue is generated from Commodity trading.

About PLUR Pluri Inc.

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Share on Social Networks: